respiratory syncytial virus (RSV)

July 17, 2014

Study identifies antibody that may fight MPV, RSV

New Vanderbilt-led research published in the Journal of Infectious Diseases has identified an antibody that shows promise in preventing and treating human metapneumovirus (MPV) and respiratory syncytial virus (RSV) — the two leading causes of respiratory infections in young children.

By Christina Echegaray

February 5, 2014

Discovery may pave way for RSV vaccine

Vanderbilt University scientists have contributed to a major finding, reported this week in the journal Nature, which could lead to the first effective vaccine against respiratory syncytial virus (RSV), a significant cause of infant mortality.

By Bill Snyder

July 18, 2013

VU researchers ‘goldsmith’ new RSV vaccine approach

Vanderbilt vaccine researchers are using gold nanotechnology to develop a new approach to making vaccines.

By VUMC News and Communications

March 4, 2013

Study finds maternal diet may predict RSV severity

An important predictor of the severity of respiratory syncytial virus (RSV) in infants may be what their mothers ate during pregnancy.

By VUMC News and Communications

September 25, 2012

Cell entry ports for cold virus

The respiratory virus HMPV uses its fusion (F) protein – which interacts with cellular receptors called integrins – to bind to and enter target cells.

By Leigh MacMillan

August 9, 2012

New therapeutic target for cold, flu viruses identified

Viruses that cause acute respiratory infections — such as human metapneumovirus (HMPV) and flu — impair a set of immune system cells that should clear the virus from the lungs.
Now, Vanderbilt University investigators have discovered the signaling pathway that disables these immune cells.